Total Payments
$10,790
2021 Payments
$198.26
Companies
4
Transactions
26
Payment Breakdown by Category
Consulting$7,491 (69.4%)
Research$1,911 (17.7%)
Travel$752.01 (7.0%)
Education$545.40 (5.1%)
Food & Beverage$90.27 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,491 | 3 | 69.4% |
| Unspecified | $1,911 | 10 | 17.7% |
| Travel and Lodging | $752.01 | 9 | 7.0% |
| Education | $545.40 | 1 | 5.1% |
| Food and Beverage | $90.27 | 3 | 0.8% |
Payments by Type
General
$8,879
16 transactions
Research
$1,911
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences Inc | $6,296 | 14 | $0 (2017) |
| PFIZER INTERNATIONAL LLC | $2,063 | 1 | $0 (2017) |
| Astellas Pharma Global Development | $1,911 | 10 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $520.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $198.26 | 2 | Astellas Pharma Global Development ($198.26) |
| 2020 | $976.83 | 5 | Astellas Pharma Global Development ($976.83) |
| 2019 | $537.78 | 2 | Astellas Pharma Global Development ($537.78) |
| 2018 | $198.17 | 1 | Astellas Pharma Global Development ($198.17) |
| 2017 | $8,879 | 16 | Gilead Sciences Inc ($6,296) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/23/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $99.13 | Research |
| Study: A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/27/2021 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $99.13 | Research |
| Study: A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 12/10/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $59.83 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 10/22/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $129.57 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 09/18/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $199.43 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/30/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $399.00 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 04/18/2020 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $189.00 | Research |
| Study: A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: HOSPITAL AND TRANSPLANT | ||||||
| 11/29/2019 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $289.45 | Research |
| Study: A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: INFECTIOUS DISEASES | ||||||
| 04/13/2019 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $248.33 | Research |
| Study: A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients • Category: INFECTIOUS DISEASES | ||||||
| 11/28/2018 | Astellas Pharma Global Development | CRESEMBA (Drug) | — | In-kind items and services | $198.17 | Research |
| Study: A PHASE 1, OPEN-LABEL, MULTICENTER, NON-COMPARATIVE PHARMACOKINETICS AND SAFETY STUDY OF INTRAVENOUS ISAVUCONAZONIUM SULFATE IN PEDIATRIC PATIENTS • Category: INFECTIOUS DISEASES | ||||||
| 12/18/2017 | PFIZER INTERNATIONAL LLC | VFEND (Drug) | Consulting Fee | Cash or cash equivalent | $2,063.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 05/12/2017 | Gilead Sciences Inc | AmBisome (Drug) | Consulting Fee | Cash or cash equivalent | $4,908.33 | General |
| Category: OTHER | ||||||
| 04/25/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $165.12 | General |
| Category: OTHER | ||||||
| 04/25/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $83.93 | General |
| Category: OTHER | ||||||
| 04/24/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $270.00 | General |
| Category: OTHER | ||||||
| 04/24/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $62.00 | General |
| Category: OTHER | ||||||
| 04/24/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $47.52 | General |
| Category: OTHER | ||||||
| 04/24/2017 | Gilead Sciences Inc | AmBisome (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: OTHER | ||||||
| 04/24/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $21.96 | General |
| Category: OTHER | ||||||
| 04/24/2017 | Gilead Sciences Inc | AmBisome (Drug) | Food and Beverage | In-kind items and services | $20.16 | General |
| Category: OTHER | ||||||
| 04/24/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $6.44 | General |
| Category: OTHER | ||||||
| 04/23/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $59.40 | General |
| Category: OTHER | ||||||
| 04/23/2017 | Gilead Sciences Inc | AmBisome (Drug) | Food and Beverage | In-kind items and services | $47.90 | General |
| Category: OTHER | ||||||
| 04/23/2017 | Gilead Sciences Inc | AmBisome (Drug) | Travel and Lodging | In-kind items and services | $35.64 | General |
| Category: OTHER | ||||||
| 04/22/2017 | Gilead Sciences Inc | AmBisome (Drug) | Education | In-kind items and services | $545.40 | General |
| Category: OTHER | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | Astellas Pharma Global Development | $976.83 | 5 |
| A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients | Astellas Pharma Global Development | $736.04 | 4 |
| A PHASE 1, OPEN-LABEL, MULTICENTER, NON-COMPARATIVE PHARMACOKINETICS AND SAFETY STUDY OF INTRAVENOUS ISAVUCONAZONIUM SULFATE IN PEDIATRIC PATIENTS | Astellas Pharma Global Development | $198.17 | 1 |
About Dr. William Steinbach, M.D
Dr. William Steinbach, M.D is a Pediatrics healthcare provider based in Little Rock, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639232416.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Steinbach, M.D has received a total of $10,790 in payments from pharmaceutical and medical device companies, with $198.26 received in 2021. These payments were reported across 26 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($7,491).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatrics, Pediatric Infectious Diseases
- Location Little Rock, AR
- Active Since 12/19/2006
- Last Updated 03/23/2023
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1639232416
Products in Payments
- AmBisome (Drug) $6,296
- VFEND (Drug) $2,063
- CRESEMBA (Drug) $1,911
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Little Rock
Anton Duke, Md, MD
Pediatrics — Payments: $267,445
Pediatrics $267,445
Matthew Kelly, M.d., M.p.h, M.D., M.P.H
Pediatrics — Payments: $58,864
Pediatrics $58,864
Shelley Crary, Md, MD
Pediatrics — Payments: $57,313
Pediatrics $57,313
Kimo Stine, Md, MD
Pediatrics — Payments: $39,188
Pediatrics $39,188
Robert Pesek, Md, MD
Pediatrics — Payments: $21,167
Pediatrics $21,167
Peyton Mills, Apn, APN
Pediatrics — Payments: $6,607
Pediatrics $6,607